Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04077723 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

A Phase 1 study of Lymphoma, Non-Hodgkin, sponsored by Hoffmann-La Roche.

Active
Registry status
Phase 1
Development phase
498
Enrollment target
20
Study locations

NCT04077723: Active Phase 1 study of Lymphoma, Non-Hodgkin, sponsored by Hoffmann-La Roche.

NCT04077723 is a Phase 1 study of Lymphoma, Non-Hodgkin that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 498 participants, above the 381-participant average among 58 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (31% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04077723, a Phase 1 study of Lymphoma, Non-Hodgkin, is active but no longer recruiting, sponsored by Hoffmann-La Roche.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
498 participants
Enrollment target
20
Study locations

Study Summary

This is a phase I/II, open-label, dose-escalation study designed to evaluate the safety, tolerability, and efficacy of englumafusp alfa (RO7227166) in participants with relapsed/refractory Non-Hodgkin's Lymphoma (r/r NHL). Englumafusp alfa will be administered by intravenous (IV) infusion in combination with obinutuzumab and in combination with glofitamab. A fixed dose of obinutuzumab (Gpt; pre-treatment) will be administered up to seven days prior to the first administration of englumafusp alfa and seven days prior to the first administration of glofitamab. This entry-into-human study is divided into a dose-escalation stage (Part I and Part II) and a dose expansion stage (Part III).

Conditions Studied

Lymphoma, Non-Hodgkin

Interventions

  • DRUG Obinutuzumab
  • DRUG Glofitamab
  • DRUG Tocilizumab
  • DRUG Englumafusp alfa

Study Locations (20)

Other

  • UZ Gent - Ghent
  • Beijing Cancer Hospital - Beijing
  • Shandong Cancer Hospital - Jinan
  • Fudan University Shanghai Cancer Center - Shanghai
  • The First Affiliated Hospital of Xiamen University - Xiamen
  • Aarhus Universitetshospital Skejby - Aarhus N

California

  • City of Hope Medical Center - Pasadena
  • University of California San Francisco - San Francisco

Texas

  • South Austin Medical Center - Austin
  • The University of Texas MD Anderson Cancer Center - Houston

Victoria

  • Peter Maccallum Cancer Centre - Melbourne
  • The Alfred Hospital - Melbourne

Colorado

  • Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center - Denver

Massachusetts

  • Beth Israel Medical Center - Boston

Missouri

  • Washington University School of Medicine - St Louis

New York

  • MSKCC - New York

Trial Details

FieldValue
Enrollment Target 498 participants
Start Date 2019-08-13
Est. Completion 2027-03-31
Phase Phase 1
Hoffmann-La Roche

909 total trials

What the registry record for NCT04077723 still lists

NCT04077723 is an interventional study that assigns participants to a tested intervention. The registered 498 participants enrollment target is mid-sized for trials with a published cap, above the 381-participant average among 58 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (31% higher).

The record links to 1 condition, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 4 interventions - of which Obinutuzumab is the first listed.

NCT04077723 names 20 study sites across 12 states, led by Other, California, Texas.

Frequently Asked Questions

What is clinical trial NCT04077723 about?

NCT04077723 is a clinical study titled "A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma". This is a phase I/II, open-label, dose-escalation study designed to evaluate the safety, tolerability, and efficacy of englumafusp alfa (RO7227166) in participants with relapsed/refractory Non-Hodgkin's Lymphoma (r/r NHL). Englumafusp alfa will be administered by intravenous (IV) infusion in combina...

What is the current status of trial NCT04077723?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 498 participants. The study started on 2019-08-13. Estimated completion is 2027-03-31.

What conditions does trial NCT04077723 study?

This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin.

What interventions are being tested in trial NCT04077723?

The interventions under investigation include: Obinutuzumab (DRUG), Glofitamab (DRUG), Tocilizumab (DRUG), Englumafusp alfa (DRUG).

Who is sponsoring clinical trial NCT04077723?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04077723 being conducted?

This trial has 20 study locations across California, Colorado, Massachusetts, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma, Non-Hodgkin

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04077723's enrollment target sits among peer trials

498 9th of 58 higher than 50 of 58 other Lymphoma, Non-Hodgkin trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lymphoma, Non-Hodgkin trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04137900 · 499 participants · Phase 1

    Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

  • NCT06733480 · 499 participants · NA

    Innovating Physical Therapy: A Pilot Study on Band Connect's Impact on Compliance, Satisfaction, and Revenue

  • NCT03175224 · 497 participants · Phase 2

    APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

  • NCT05301816 · 497 participants · NA

    PDN Post Market, Multicenter, Prospective, Global Clinical Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04077723, the US trial registry maintained by the National Library of Medicine. NCT04077723 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.